Medicine
Epigenetic Regulation of Drug-Metabolizing Enzymes in Cancer Therapy
Quick fact
Tumors can switch off genes for drug-metabolizing enzymes through DNA methylation or histone modifications, making them resistant to chemotherapy, yet this process is reversible—unlike genetic mutations—offering a target for new drugs.
Why this is interesting
You might assume that your genes are fixed, but your cells can turn drug-processing enzymes on or off without changing the DNA code. How could this affect whether a cancer drug works or harms you?
Read the full explanation
Understanding Epigenetic Regulation of Drug-Metabolizing Enzymes in Cancer Therapy
Think of your DNA as a cookbook with recipes for enzymes that process drugs. Epigenetic marks are like sticky notes and bookmarks that tell the cell which pages to open or keep closed. In cancer, these marks can silence genes for drug-metabolizing enzymes, so the tumor may not activate a prodrug or may fail to detoxify a toxic compound. This is not a change in the recipe itself, but in the accessibility of the recipe.
A deeper explanation
Drug-metabolizing enzymes (DMEs), particularly cytochrome P450 enzymes (CYPs), are encoded by genes whose expression is controlled by epigenetic mechanisms. DNA methylation at promoter CpG islands typically silences gene transcription, while histone modifications (e.g., acetylation vs. deacetylation) can alter chromatin structure, making genes accessible or inaccessible to transcription factors. In cancer, aberrant DNA methylation and histone deacetylation can downregulate or upregulate DMEs, leading to altered drug metabolism. This can result in reduced activation of prodrugs (like cyclophosphamide) or decreased detoxification of active metabolites, affecting both efficacy and toxicity. Unlike genetic mutations, these epigenetic changes are reversible using DNA methyltransferase inhibitors (e.g., 5-azacitidine) and histone deacetylase inhibitors (e.g., vorinostat), which can re-express silenced enzymes. This opens the door for combination therapies where epigenetic priming enhances the effectiveness of conventional chemotherapy.